Shingrix vaccine under the microscope: can it shield patients on Immune-Weakening drugs?

NCT ID NCT07534007

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how the Shingrix vaccine (for shingles) works in people with psoriasis or myelofibrosis who are taking drugs that weaken their immune system. Researchers will compare their immune response to that of similar patients not on these drugs. The goal is to understand if the vaccine still provides strong protection in these vulnerable groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fondazione IRCCS Policlinico San Matteo di Pavia

    RECRUITING

    Pavia, Lombarda, 27100, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.